CRL's PB Ratio is ranked worse than 74.36% of 195
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.02
vs CRL: 3.81
During the past 12 months, Charles River Laboratories International's average Book Value Per Share Growth Rate was -8.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 3.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 9.40% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 17.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Charles River Laboratories International was 50.70% per year. The lowest was -23.60% per year. And the median was 10.10% per year.
Back to Basics: PB Ratio
Charles River Laboratories International (NYSE:CRL) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Charles River Laboratories International PB Ratio Related Terms
Charles River Laboratories International PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Charles River Laboratories International PB Ratio Chart
Charles River Laboratories International Annual Data
For the Diagnostics & Research subindustry, Charles River Laboratories International's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Charles River Laboratories International PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Charles River Laboratories International's PB Ratio distribution charts can be found below:
* The bar in red indicates where Charles River Laboratories International's PB Ratio falls into.
Charles River Laboratories International PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Charles River Laboratories International (CRL) has a PB Ratio of 3.81 as of Jul. 01, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Charles River Laboratories International and its competitors. This is 15% below median its historical median of 4.50. Over the past decade, Charles River Laboratories International's PB Ratio has ranged from 1.53 to 9.96. According to the industry distribution chart, Charles River Laboratories International ranks #145 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 74.4%.
Is Charles River Laboratories International's PB Ratio too high?
Charles River Laboratories International's current PB Ratio of 3.81 is 15% below median its 10-year median of 4.50. Over the past 10 years, this metric has ranged from a low of 1.53 to a high of 9.96. The Medical Diagnostics & Research industry median PB Ratio is 2.02. Charles River Laboratories International's value of 3.81 is 88.6% above this industry median. Based on the distribution chart, Charles River Laboratories International ranks #145 out of 195 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Charles River Laboratories International has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Charles River Laboratories International's PB Ratio compare to RVTY and QGEN?
According to the Medical Diagnostics & Research industry distribution chart, Charles River Laboratories International ranks #145 out of 195 companies for PB Ratio. This places Charles River Laboratories International in the lower half of its industry. The industry median PB Ratio is 2.02. Charles River Laboratories International's value of 3.81 is 88.6% above this benchmark. Historically, Charles River Laboratories International's own PB Ratio has ranged from 1.53 to 9.96 over the past decade. While the company's 10-year median is 4.50 vs. the industry median of 2.02, Charles River Laboratories International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.02, based on 195 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Charles River Laboratories International's current PB Ratio of 3.81 is 88.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Charles River Laboratories International and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Charles River Laboratories International's current PB Ratio is 3.81, which is 15% below median its own 10-year median of 4.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Charles River Laboratories International stock overvalued right now?
Based on GuruFocus' analysis, Charles River Laboratories International (CRL) is currently considered Modestly Overvalued. The stock's GF Value™ is $194.53, compared to a current price of $226.79 — trading 16.6% above its estimated fair value. The current PB Ratio is 3.81, which is 15% below median its 10-year median of 4.50 and 88.6% above the Medical Diagnostics & Research industry median of 2.02. Charles River Laboratories International's overall GF Score™ is 70/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Charles River Laboratories International (CRL), the current PB Ratio is 3.81 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Charles River Laboratories International (CRL) Overvalued in 2026?
Based on GuruFocus' analysis, Charles River Laboratories International stock appears to be overvalued.
The current stock price of $226.79 is trading 16.6% above its estimated GF Value™ of $194.53.
GuruFocus considers Charles River Laboratories International to be Modestly Overvalued.
Key valuation signals for CRL:
PB Ratio: 3.81 (15% below median its 10-year median of 4.50)
GF Value™: $194.53 vs. price of $226.79 (16.6% above fair value)
Industry Position: 88.6% above the Medical Diagnostics & Research median (#145 of 195)
No single metric tells the full story. See the CRL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Charles River Laboratories International Business Description
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
70GF Score
Get the complete analysis for CRL
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRL has been successfully added to your 
